Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentostatin, Alemtuzumab, and Rituximab in Relapsed/Refractory CLL/SLL
NCT00669318Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2008
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentostatin, alemtuzumab and rituximab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Mayo Clinic. Primary endpoint: Complete Response Rate up to 5 months. Started Jul 2008; status: completed.
02
Drugs
pentostatinalemtuzumabrituximab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00669318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00669318.